Showing 581-590 of 3245 results for "".
Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaRevance Data, AD Updates, FDA Actions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-revance-data-ad-updates-fda-actions/18463/A US District Court judge blocks Stratus Pharmaceuticals of Miami and Sonar Products of Carlstadt, NJ from selling substandard dermatological products. Newly identified mutations in a gene called CARD11 may lead to atopic dermatitis. Surprising new evidence suggests atopic dermatitis is associated wWhy Your Dermatology Practice Should Be On Instagram
https://practicaldermatology.com/topics/practice-management/dermpracticeinstagram/18473/Instagram is different from most social networks. And it's growing quickly with skyrocketing mobile technology use. It's a marketing opportunity for dermatologists, especially those interested in cosmetic procedures. Learn how to use Instagram for your practice marketing and outreach in this Ekwa.coNeuromodulators in Medical Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/neuromodulators-in-medical-dermatology/18520/Physicians are exploring the effects of botulinum toxins on several medical dermatology conditions. Erin Gilbert, MD talks to Joel Cohen, MD about her experience treating rosacea, and discusses the need for better randomized trials to explore treatment options.Rhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rhofade-approved-sun-leaves-acne-behind-radiesse-turns-10/18552/The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking upKeys for Practice Success in 2017
https://practicaldermatology.com/topics/practice-management/keys-for-practice-success-in-2017/20838/The way patients choose physicians is changing, so physicians need to change the way they grow their practices.How to Optimize Twitter for your Practice
https://practicaldermatology.com/topics/practice-management/how-to-optimize-twitter-for-your-practice/18558/Twitter offers practices numerous opportunities to derive great business value. It's essential to identify specific conversations, and then use the information to optimize marketing in targeted areas. This Ekwa.com Marketing Educational video explains how dermatology practices can use Twitter to effBenchside Dispatches Psoriasis
https://practicaldermatology.com/topics/psoriasis/benchside-dispatches-psoriasis/20922/An interview with Alice Gottlieb, MD, PhDRisk In Your Portfolio
https://practicaldermatology.com/topics/practice-management/risk-in-your-portfolio/18588/Do you know your risk score? Physicians must understand their personal tolerance for risk as well as the level of risk in their current portfolios. If there is a mismatch, how do you rectify the disconnect. Bob Peelman, CFP, of OJM Group, explains. ABOUT THE AUTHORMeaningful Approaches to Vitiligo
https://practicaldermatology.com/topics/general-topics/meaningful-approaches-to-vitiligo/18599/As science continues to uncover more about vitiligo and its treatment, dermatologists have more options than ever. But there's still work to be done. In this edition of Ask an Expert, host Adam Friedman, MD talks to John E. Harris, MD, PhD, Director of the Vitiligo Clinic and Research Center at Univ